⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Phase IIIGLP-1

Compound 61664

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061664
Risk Class
MODERATE
Last Audit
Jun 1, 2108

Research Abstract

GLP-1 candidate engineered for cellular repair initiatives with automated dossier coverage.

Compound 61664 is a glp-1 asset inside glp-1 innovation track initiatives, optimized for cellular repair and tissue regeneration.

The dossier currently sits in phase iii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061664 with updates logged 2108-06-01.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Cellular repairTissue regeneration

Nomenclature

CX-61664GLP-1 Program 61664

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061664
  2. [2] Operations Pulse • GLP-1 innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61664